oxybutynin Tablets, extended release (ER) 5 mg, 10 mg, 15 mg
Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
FDA, WHO
Manufacturer #675
A pharmaceutical manufacturer focused on developing and supplying specialized and generic pharmaceutical products across multiple dosage forms such as oral solids, oral liquids, and drug-device combinations. The company operates integrated development and manufacturing facilities that follow established quality standards and provide both commercial supply and contract development services for regulated markets. Its broad formulation portfolio enables flexible and reliable production of pharmaceutical products for global partners.
Oxybutynin is a medication used to treat overactive bladder. Suppliers market it as oxybutynin oral tablets, transdermal patches, topical gels and it is available as immediate and delayed-release formulations.
The drug was first approved for medical use in 1975, and by now has reached widespread use, with over 6 million prescriptions registered yearly in the U.S. alone. Multiple manufacturing companies and drug vendors populate the global oxybutynin market, including major suppliers such as Sanofi-Aventis, Mylan, Accord Healthcare, and many others.
Suppliers market both generic and trade name oxybutynin medications. Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform.
The retail prices per 60 (5mg) tablets of oxybutynin fall into an approximate range of 7.50 EUR to 10.00 EUR.